Oncostatin M (OSM), a cytokine of the interleukin-6 family, induces growth arrest and differentiation of osteoblastic cells into glial-like/osteocytic cells. Here, we asked whether OSM regulates apoptosis of normal or transformed (osteosarcoma) osteoblasts. We show that OSM sensitizes cells to apoptosis induced by various death inducers such as staurosporine, ultraviolet or tumor necrosis factor-a. Apoptosis is mediated by the mitochondrial pathway, with release of cytochrome c from the mitochondria to the cytosol and activation of caspases-9 and -3. DNA micro-arrays revealed that OSM modulates the expression of Bax, Bad, Bnip3, Bcl-2 and Mcl-1. Pharmacological inhibitors, dominant-negative signal transducer and activator of transcriptions (STATs), stable RNA interference and knockout cells indicated that the transcription factors p53 and STAT5, which are activated by OSM, are implicated in the sensitization to apoptosis, being responsible for Bax induction and Bcl-2 reduction, respectively. These results indicate that, in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating (i) activation and nuclear translocation of STAT5 and p53 and (ii) an increased Bax/Bcl-2 ratio. Therefore, association of OSM with kinase inhibitors such as Sts represents new therapeutic opportunities for wild-type p53 osteosarcoma.
Introduction
Apoptosis, or programmed cell death, plays an important role in embryonic development and in the control of cell number during the life. Deregulation of apoptosis occurs in a lot of diseases, and more particularly in the tumorigenesis process. The tumor suppressor p53 plays a central role in the control of genomic integrity by inducing cell-cycle arrest or apoptosis in damaged cells, and its inactivation is implicated in half of all human tumors (Haupt et al., 2003; Oren, 2003) . Osteosarcomas are rare primitive bone tumors arising from osteoblasts, the cells responsible for bone apposition. The molecular etiology of osteosarcoma is still controversial but it could be related to the loss of function of Rb and/or p53 (Wadayama et al., 1994; Fuchs and Pritchard, 2002) . Patient survival is closely related to the response of the tumor cells to chemotherapy, reaching 60-70% at 5 years in the best series and only 30% when pulmonary metastases are detected at the time of diagnosis. Thus, a better understanding of osteoblast/osteosarcoma biology is needed to develop alternative or adjuvant therapeutic strategies.
Oncostatin M (OSM) is a cytokine of the interleukin-6 (IL-6) family. Binding of OSM to its receptor complex (gp130-OSMRb) triggers the activation of two main pathways: the JAK-signal transducer and activator of transcription (STAT) (with STAT1, STAT3 and STAT5) and the mitogen-activated protein kinase (with extracellular signal-regulated kinase (ERK)½) signaling pathways (Auguste et al., 1997; Chen and Benveniste, 2004) . Like other IL-6 type cytokines, OSM plays a crucial role in inflammation, immune response, hematopoiesis, liver and neuronal regeneration (Kamiya et al., 1999; Chen and Benveniste, 2004) . Specific effects of OSM include the renal inflammatory response (Baumann et al., 2000) and differentiation of fetal hepatocytes (Kamiya et al., 1999) . Moreover, OSM is the most active IL-6 type cytokine to inhibit, via STAT3 and p21
WAF1
, the proliferation of various solid tumor cell lines such as osteosarcoma (Bellido et al., 1997 , melanoma, hepatoma and breast cancer (Grant and Begley, 1999) .
The inhibitory effect of OSM on osteosarcoma cell proliferation is tightly coupled to the induced differentiation. We have previously showed that OSM has opposing effects on osteosarcoma or non-transformed osteoblasts, depending on the stage of differentiation (Chipoy et al., 2004) . On poorly differentiated cells, OSM enhances osteoblastic markers expression, and their capacity to form mineralized bone nodules. On the contrary, OSM reduces these markers on mature osteoblasts and osteosarcoma with an osteoblastic phenotype. Moreover, OSM induces glial fibrillary acidic protein expression, indicating a glial-like or osteocytic terminal differentiation. The kinase PKCd and the transcription factor STAT3 are implicated in these effects of OSM (Chipoy et al., 2004) .
In human bone, 50-70% of osteoblasts undergo apoptosis and only a minority becomes osteocytes or lining cells (Jilka et al., 1998) . Hormones, growth factors and cytokines (estrogen, tumor necrosis factor-a (TNFa), Fas ligand and transforming growth factor-b) in the bone environment control osteoblast apoptosis, thus influencing bone formation in diseases such as osteoporosis (Jilka et al., 1998) . Given the strong interaction between proliferation, differentiation and apoptosis, and their key role in regulating osteoblast/osteocyte functions, we asked here whether OSM could also regulate apoptosis of normal or transformed osteoblasts. Few studies focused on the effects of OSM on apoptosis, and the conclusions were opposite according to the model. A recent study has shown that OSM induces apoptosis in adrenocortical Y-1 tumor cell line, implicating the JAK-STAT pathway and caspase-3 activation (Auernhammer et al., 2004) . On the other hand, OSM was able to protect MG63 osteosarcoma cells from apoptosis induced by an anti-Fas antibody by preventing the loss of Bcl-2 protein (Jilka et al., 1998) .
Here, we show that OSM sensitizes various osteosarcoma cell lines or osteoblastic cells to apoptosis induced by Staurosporine (Sts) or other death inducers. Apoptosis induced by OSM þ Sts is mediated by the mitochondrial pathway, with an increased Bax/Bcl-2 ratio, cyt c release from the mitochondria and activation of caspases-9 and -3. The transcription factors STAT5 and p53 are implicated in this sensitization, being responsible for Bcl-2 reduction and Bax induction respectively.
Results

OSM enhances cell death in association with different death inducers
To test whether OSM could regulate apoptosis in osteosarcoma cells, we examined the effects of OSM pretreatment on cell death induced by different death inducers. First, OSRGA rat osteosarcoma cells were pretreated with OSM (100 ng/ml) for 3 days, and then a low dose of Sts (100 nM), a protein kinase inhibitor known to induce apoptosis, was added overnight. While neither OSM nor Sts alone induced significant cell death, pretreatment with OSM sensitized OSRGA cells to Sts-induced cell death (viability reduced by more than 60%; Figure 1a) . A minimum of 24-48 h of OSM pretreatment was needed to observe the sensitization effect of OSM (data not shown). Higher concentrations of Sts (1 mM) induced cell death in OSRGA cells pretreated or not with OSM (data not shown and Figure 2a ).
Next, we examined the effects of other death inducers like ultraviolet (UV), serum starvation and TNF-a treatment (Figure 1b-d) . Because OSRGA cells were resistant to cell death induced by TNF-a, we also made a pretreatment with interferon-g (IFN-g) which is known to enhance cell death most presumably by inducing death receptors expression (Jilka et al., 1998) . Thus, OSRGA cells were pretreated with OSM (and/or IFNg) for 3 days, and then death signals were applied: 500 J/m 2 for UV radiation (followed by 24 h of culture), 24 h for serum starvation and 3 days for TNF-a. With this three death inducers, OSM-treated cells underwent cell death (50-60% of dead cells), whereas the death inducers alone were far less effective. Thus, these results indicated that OSM can sensitize OSRGA cells to cell death induced by different death inducers, whatever their mechanism of proapoptotic action.
Apoptosis induced by OSM þ Sts is caspase dependent
To characterize better the sensitization effect of OSM, we focused on the combination OSM þ Sts. OSRGA cells were treated with or without OSM for 3 days, and increasing concentrations of Sts were added overnight. INF-g (100 ng/ml) with or without OSM (100 ng/ml) for 3 days. Then cells were treated with OSM and/or TNF-a (100 ng/ml) for three additional days. Viability was quantified by Trypan blue staining. Bars represent the mean7s.d. FBS, fetal bovine serum; IFN, interferon; OSM, oncostatin M; UV, ultraviolet.
As shown in Figure 2a , viability of OSM-treated cells was strongly reduced compared to non-treated cells. The IC 50 were around 10 nM of Sts on OSM-treated cells and more than 1 mM of Sts on non-treated cells.
Through time-lapse experiments, cell death ( Figure 2b and Supplementary movies 1-4) was analysed in a timedependent manner. With the combination OSM þ Sts, 50% of the cells died within 8 h versus 5-7% with OSM or Sts alone. At the end of the experiments (14 h), more than 70% of the cells died when treated with OSM þ Sts. Typical apoptotic figures were observed with membrane blebbing and nuclear condensation (Supplementary movies 1-4). Apoptosis was confirmed by Hoechst staining showing extensive nuclear fragmentation (data not shown).
To investigate the apoptotic pathway implicated, localization of cyt c and activation of several caspases were studied by western blot analysis (Figure 2c ). While treatment of these cells with OSM or Sts alone did not induce cleavage of caspases-3 or -9, these proteases were effectively cleaved and activated with the combination OSM þ Sts. Similarly, release of cyt c from the mitochondria to the cytosol was observed only with OSM þ Sts. Treatment of OSRGA cells with OSM and UV also induced activation of caspases-3 and -9 (Supplementary Figure 1) . Moreover, the use of the pan-caspase inhibitor (Z-Val-Ala-Asp(OMe)-CH 2 F) (Z-VAD-FMK) prevented apoptosis induced by OSM þ Sts, although this prevention was not total (Figure 2d ). All these results suggested that OSM pretreatment followed by Sts or other death stimuliinduced apoptosis in OSRGA cells by a mechanism mainly dependent on caspase activation and implicating the mitochondrial caspase-9 specific pathway.
OSM modulates expression of proapoptotic and anti-apoptotic Bcl-2 family proteins As the mitochondrial apoptotic pathway is regulated by the Bcl-2 family of proteins, we examined the effects of OSM on their mRNA and protein expression levels in OSRGA cells. We performed similar analyses on MG63 human osteosarcoma cells that are effectively growth inhibited by OSM (Table 1 ; Bellido et al., 1997) but are resistant to cell death induced by OSM þ Sts (Table 1 and Supplementary Figure 2e) . DNA micro-array experiments showed that 3 days of OSM treatment on OSRGA cells were able to increase the mRNA level of proapoptotic molecules, such as Bax, Bad, Bim, Bnip3, Bok and Bcl-xs (Table 2) . Conversely, the anti-apoptotic member Bcl-2 was reduced by OSM, whereas Mcl-1 and Bcl-xl were increased. Several of these results were confirmed at the protein level by western blot experiments ( Figure 3a and Table 2 ). Indeed, Bad and Bax proteins were upregulated more than twofold in OSRGA cells after OSM-treatment whereas Bcl-xl was increased only 1.5-fold. On the contrary, Bcl-2 and the phosphorylated inactive form of Bad were downregulated. All these modulations occurred after 24-48 h of OSM treatment (Figure 3b ). We did not observe modulation in Bim or Bcl-xs protein levels despite the OSM-induced expression of their mRNA. At the concentration used (100 nM), Sts had no effect on expression of these proteins (Figure 3a) .
In MG63 cells, OSM did not induced Bax or Bad expression but was still able to reduce Bcl-2 mRNA or protein levels (Table 2 and Supplementary Figure 2f ). An increased Bnip-3 and Mcl-1 level, as well as a decreased Bak level, was also observed. Because MG63 cells have a rearrangement mutation of the p53 gene, which results in disruption of p53 protein function (Chandar et al., 1992) , we then asked whether OSM could modulate the expression/activation of this transcription factor known to regulate expression of several Bcl-2 members. In OSRGA cells (Figure 3a and b) but not in MG63 cells (Supplementary Figure 2f) , we observed an induced phosphorylation of p53 after 24-48 h of OSM treatment, in correlation with an accumulation of total p53. The cellular localization of p53 was then studied by immunocytochemistry (Figure 3c ). After 15 min of OSM treatment, we observed a translocation of p53 in the nucleus and after 24 h, p53 could be detected in the nucleus and cytosol. Bellido et al., 1997; Chipoy et al., 2004) . Similarly, in both OSRGA ( Figure 3b ) and MG63 cells (data not shown; Bellido et al., 1998), p21 WAF1 was transiently induced within 6-24 h of OSM treatment, whereas transient phosphorylation of Rb was observed early after 15 min of cytokine treatment. SaOS2 cells were also found resistant to cell death induced by OSM þ Sts, but sensitive to growth inhibition induced by OSM (Table 1) . Altogether, these results indicated that the cytostatic effect of OSM is not associated with cell death in all osteosarcoma cell lines, pointing to a specific signaling pathway for apoptosis, distinct from the one used for growth arrest.
OSM induces cell death in association with specific kinases inhibitors Sts is a well-known kinase inhibitor and we observed that it prevented phosphorylation/activation of ERK1/ 2, protein kinase Cd (PKCd) and Akt by OSM ( Figure 4a ). Thus, we tested whether specific kinase inhibitors could also induce apoptosis in association with OSM. Activity and specificity of these kinase inhibitors on signal transduction pathways activated by OSM were described previously (Chipoy et al., 2004) . OSRGA cells were pretreated with inhibitors for 1 h and OSM was added or not for 3 days. Figure 4b shows that PI3K, Akt and PKCd inhibitors (respectively LY, AktI and Rottlerin), when associated with OSM, induced a reduction of at least 40% of the cell viability, while the ERK½ inhibitor (UO) had little effect. Kinase Cells were treated with OSM for 3 days and Sts was added overnight. The percentage of dead cell (apoptosis) was determined by trypan blue exclusion and ranked as follow: +++ (>80%), ++ (between 60 and 80%), + (o60%) and -(no apoptosis).
b OSRGA, POS and UMR106: p53 status was defined by immunocytochemistry using a p53 antibody specific for the wild-type (wt) protein. For other cell lines, the p53 status was already defined in the literature (Diller et al., 1990; Casey et al., 1991; Chandar et al., 1992; Florenes et al., 1994; Wei, 2005) . c STAT5 activation was studied after 15 min of OSM treatment by western blotting experiment using a P-STAT5 antibody. Empty cases, not done. 
Abbreviations: OSM, oncostatin M. The relative fold changes in transcript or protein expression between OSM treated and control samples were ranked as follows: ÀÀ (o0.5), À (between 0.5 and 0.8), 0 (between 0.8 and 1.25), + (between 1.25 and 2) and ++ (>2 inhibitors alone did not reduce cell viability below 80%. These results suggested that activation of the PI3K/Akt and PKCd pathways by OSM induced anti-apoptotic signals, and that at least some of the Sts proapoptotic effects were due to inhibition of these kinases.
STAT5 is necessary for apoptosis induced by OSM þ Sts STATs represent others transduction pathways known to be activated by OSM. Western blot analysis showed that OSM induced a transient (at 15 min) phosphorylation/activation of STAT1, STAT3 and STAT5 in OSRGA cells (Figure 5a ). Two highly homologous and redundant STAT5 isoforms, STAT5a and STAT5b exist (Buitenhuis et al., 2004) and could be detected in OSRGA cells (Figure 5a , bottom panel). OSM treatment clearly modified the electrophoretic migration of STAT5b, indicating that at least this isoform was activated by OSM as shown previously (Auguste et al., 1997) . By immunocytochemistry, we observed a nuclear translocation of STAT5 after 15 min of OSM treatment (Figure 5b) . By 24-48 h of OSM treatment, STAT5 could be detected in the cytoplasm and nucleus, this regulation being very similar to the one observed with p53 (compare Figures 3c and 5b) .
To evaluate the role of these pathways in the sensitization effect of OSM, OSRGA cells were transfected with dominant-negative STAT1, 3 or 5b (dnS1, 3 or 5b) expression vectors (Figure 5c ). These dominant negative STATs were previously shown to prevent various promoters and genes induction in HepG2 and OSRGA cells (Baumann et al., 2000; Chipoy et al., 2004) . While neither dnS1 nor dnS3 modified the cell viability, transfection of dnS5b was able to prevent apoptosis induced by OSM þ Sts (Figure 5d ). Similarly, only dnS5b was able to prevent the caspase-3 activity (1 mM, 1 h) and then OSM (100 ng/ml) was added for 15 min. Whole cells lysates were analysed by western blotting for phospho-ERK1/ 2 (Thr202/Tyr204; P-ERK), phospho-PKCd (Thr505; P-PKCd), phospho-Akt (Ser476; P-Akt) and total Akt. (Figure 5e ). These results suggested that activation of STAT5 by OSM is necessary for its proapoptotic effect, whereas activation of STAT1 and STAT3 seems to be dispensable.
To investigate the role of STAT5 in the modulation of the Bax/Bcl-2 ratio, the expression levels of these proteins were studied by western blotting. Figure 5f shows that Bcl-2 expression was strongly reduced following OSM treatment in control and full length S5b transfected cells, but in dnS5b transfected cells the loss of Bcl-2 was partly prevented. On the other hand, the Bax level was increased after OSM treatment even in dnS5b or full length S5b transfected cells. Similarly, Transfected cells were treated with OSM (100 ng/ml for 3 days) and Sts (100 nM for 5 h). Caspase-3 activity was determined on cell lysates by a fluorometric assay. (f) OSRGA cells were transfected with dnS5b or total STAT5b (tot S5b) and treated with OSM for 48 h. Bax, Bcl-2, Bad and p21 expression was estimated by western blotting. (g) ShLacZ or shSTAT5 OSRGA cells were treated with OSM (100 ng/ml for 15 min) and analysed for phospho-STAT5 or total STAT5 by western blotting. Protein loading was controlled with an anti-actin. (h) ShLacZ or shSTAT5 OSRGA cells were treated with OSM (100 ng/ml for 3 days) and then Sts was added overnight as indicated. Cell viability was assessed by an XTT assay. Results are expressed as percent of cell death induced by OSM þ Sts over cell death induced by Sts alone. In all cases, bars represent the mean7s.d. and similar results were observed in three independent experiments. OSM, oncostatin M; STAT, signal transducer and activator of transcription; Sts, staurosporine.
Proapoptotic effects of OSM on osteosarcoma cells C Chipoy et al induction of p21 WAF1 or Bad by OSM was not inhibited by the dnS5b (Figure 5e ). These results indicated that STAT5 is necessary for full Bcl-2 reduction by OSM but not for the induction of Bax, p21 WAF1 or Bad. To confirm the implication of STAT5 in cell death induced by OSM þ Sts, we stably knocked down both death induced by OSM þ Sts, although this protection was only partial, especially at high Sts concentrations (30% reduced cell death with 100 nM Sts; Figure 5h ). Considering that STAT5 was reduced by 70%, these results suggested that STAT5 molecules were not rate limiting for cell death in OSRGA cells. However, together with the results obtained with the dnS5b, these data indicated that STAT5 has a significant role in apoptosis induced by OSM þ Sts.
p53 is required for Bax induction It is well described that p53 can bind to the Bax promoter and enhance its transcription (Thornborrow and Manfredi, 1999) . Since p53 was activated after OSM treatment (Figure 3) , we examined the effect of a p53 inhibitor, pifithrin a. As shown in Figure 6a , pifithrin a partially prevented the cell death induced by the combination OSM þ Sts (viability of 48% in absence versus 72% in presence of pifithrin a). Moreover, induction of caspase-3 activity was reduced by the use of pifithrin a by 33% (Figure 6b ). Implication of p53 in Bax induction was also confirmed by western blotting experiments. When cells were pretreated with pifithrin a, OSM was not able to upregulate Bax at the protein level, whereas Bcl-2 was still decreased (Figure 6c ). In the absence of OSM treatment, pifithrin a was also found to reduce the basal level of Bax. In contrast, pifithrin a did not prevent induction of p21 WAF1 or Bad by OSM (Figure 6c ). The role of p53 in sensitization to apoptosis by OSM was then confirmed by the screening of cell lines with different p53 status (Figure 6d , Table 1 and Supplementary Figure 2 for ROS, ST2 and MG63 cells). Indeed, the combination OSM þ Sts did not induce apoptosis on cell lines which have a defective p53 (mutated or null), like MG63, SaOS2 and MNNG-HOS human osteosarcoma cell lines (Diller et al., 1990; Casey et al., 1991; Chandar et al., 1992; Wei, 2005) . The resistant U2OS cells are known to express wild-type p53, but inactivated by an excess of its negative regulatory partner mdm2 (Florenes et al., 1994) and/or loss of its activator p14 ARF (Stott et al., 1998) . Moreover, OSM was unable to activate STAT5 in these cells (Table 1) . In contrast, osteosarcoma cells with a wild-type p53 -OSRGA, ROS, POS À were all sensitized to apoptosis driven by OSM except UMR106 cells. On this resistant cell line, OSM activated STAT3 but not STAT5 (Table 1) , suggesting again that both p53 and STAT5 need to be activated. In the case of non-tumoral osteoblastic cells, OSM þ Sts induced apoptosis on cells with a high rate of proliferation, such as the ST2 stromal cells, MC3T3 calvaria cells and bone marrow mesenchymal stem cells (BMSC) but had no effect on mature slowly proliferating osteoblasts in spite of a wild-type p53 (Table 1 and Supplementary Figure 2) ; suggesting a link between the OSM þ Sts induced apoptosis and the cell cycle. In ST2 cells, OSM induced phosphorylation of p53 and expression of Bax, whereas Bcl-2 was decreased (Supplementary Figure 2d) . Moreover, sensitization to cell death by OSM was not restricted to osteoblastic cells, as MCF-7 breast cancer cells and mouse embryonic fibroblasts (MEF) were found sensitive to apoptosis induced by OSM þ Sts (Table 1) .
Altogether, these experiments suggested that p53, together with STAT5, is required for sensitization of osteosarcoma cells to apoptosis by OSM. However, this conclusion was tempered by the fact that these cell lines might differ in ways other than p53 and STAT5. We therefore analysed parental colorectal HCT116 cells containing wild-type p53 (p53 þ / þ ) and HCT116 cells with targeted deletions of both p53 alleles (p53 À/À cells obtained by targeted homologous recombination; Bunz et al., 1998) . Whereas OSM increased the sensitivity of p53 þ / þ cells for Sts, this cytokine did not affect activation of caspase-3 or cell death induced by Sts in p53 À/À cells (Figure 6e and f) , thus confirming the key role of p53 in apoptosis induced by OSM þ Sts. Moreover, in p53 þ / þ HCT116 cells OSM induced phosphorylation of p53 (2.3-fold) and expression of Bax (1.8-fold), whereas in p53 À/À cells OSM had no effect on Bax expression (Figure 6d ), thus confirming that OSM induced Bax expression through p53 activation.
Discussion
In this study, we demonstrate for the first time that OSM sensitizes osteosarcoma and non-transformed osteoblastic cells to apoptosis induced by a variety of death inducers. OSM plus Sts induce cyt c release, activation of caspases-3 and -9 and a pan caspases inhibitor prevents full cell death induced by this combination, suggesting that OSM sensitizes cells to the mitochondrial apoptotic pathway. Indeed, Sts and UV are known to induce Bax conformational changes and its insertion in the outer mitochondrial membrane, leading to caspases-9 and -3 activation and cell death (Kashkar et al., 2005) . TNF-a activates the death receptor pathway, characterized by activation of caspase-8 and then caspase-3. However, extrinsic and intrinsic apoptotic pathways can be linked by the proapoptotic protein Bid. After activation by caspase-8, truncated Bid triggers relocalization of Bax in the mitochondria, release of cyt c and apoptosome formation (Eskes et al., 2000) .
Thus, all these apoptotic signals can activate the mitochondrial pathway, but how does OSM sensitize the mitochondria to suboptimal dose of apoptotic agents? Our results indicate that OSM enhances the expression of various proapoptotic Bcl-2 members, most notably Bax, Bad and Bnip-3, while the anti-apoptotic protein Bcl-2 is reduced. However, these changes are not sufficient to trigger cell death, because none of the cells tested so far undergoes apoptosis when treated with OSM alone. Also not directly tested in this study, it is therefore possible that OSM enhanced the cytoplasmic inactive pool of Bax and that following an apoptotic stimulus such as Sts or UV, a large amount of Bax undergoes a localization shift to the mitochondria, thus triggering cyt c release as well as caspases-9 and -3 activation. A decreased Bcl-2 and increased Bad level would further enhance this death pathway, while the induced expression of the anti-apoptotic Mcl-1 protein would mitigate it. Moreover, OSM could regulate other proteins important for the mitochondrial apoptotic pathway or more generally for cell death. Indeed, micro-array analyses indicated that OSM modulates the mRNA expression of Apaf-1, cathepsin D and L, Hif-1 (hypoxia-inducible factor-1), COX-VIII (cyclooxygenase-VIII) and superoxide dismutase-2 for example. Further experiments are needed to determine their respective role in apoptosis induced by OSM.
As described previously, binding of OSM to its specific receptor triggers the activation of kinases such as ERK½, Akt and PKCd, and of the transcription factors STAT1, 3 and 5 (Auguste et al., 1997; Chen and Benveniste, 2004; Chipoy et al., 2004) . Here, the use of specific kinase inhibitors indicated that the PI3K/Akt and the PKCd pathways have an anti-apoptotic function in osteosarcoma, whereas STAT5 appears necessary for caspase-3 activation and apoptosis. Thus, OSM is able to activate both proapoptotic and anti-apoptotic signals, this balance being necessary to avoid cell death as observed with OSM alone. When treated with kinase inhibitors such as Sts, osteosarcoma cells then undergo apoptosis due to an excess of STAT5 proapoptotic signals.
The role of STATs in apoptosis has been previously studied. Whereas STAT1 is clearly known to trigger apoptosis, STAT3 seems to have proapoptotic or antiapoptotic effects depending on the cell type (Chapman et al., 1999; Stephanou et al., 2000; Battle and Frank, 2002) . Most of the studies about STAT5 described it as an anti-apoptotic factor, leading to oncogenesis when activated (Battle and Frank, 2002; Debierre-Grockiego, 2004; Heath and Cross, 2004) . Nevertheless, hyperphosphorylation of STAT5 after IL-3 treatment was shown to induce apoptosis on myeloid cells expressing a constitutively active STAT5 mutant. On these cells, the affinity of STAT5 to the promoter regions of the target genes seems to be modified by the degree and the duration of its phosphorylation, resulting in opposite effects, like proliferation, differentiation or apoptosis (Nosaka et al., 1999) . Here we demonstrated, by using both dominant negative STAT5 and STAT5 knock down, that this transcription factor was necessary for full Bcl-2 reduction and apoptosis induced by OSM in osteosarcoma cells.
Several lines of evidence indicate that p53 is also implicated in the sensitization to apoptosis by OSM. First, we could detect a nuclear translocation followed by an accumulation and phosphorylation/activation of p53 after OSM treatment. The exact molecular mechanisms implicated in p53 activation by OSM are currently not known but could rely on interaction with other activated kinases or STATs. Thus, a recent publication showed that p53 can interact with the transcription factor STAT1 in response to DNA damage, STAT1 acting as a co-activator for p53 (Townsend et al., 2004) . Second, a p53 transcriptional inhibitor, pifithrin a, reduces caspase-3 activation and cell death induced by OSM þ Sts. Interestingly, pifithrin a totally prevented Bax induction by OSM, suggesting that induction of this proapoptotic protein was also important for sensitization to apoptosis. Third, osteosarcoma cell lines with a defective or inactivated p53 are not sensitized to cell death induced by OSM þ Sts. The key role of p53 is also confirmed in HCT116 cells with targeted deletions of p53. Therefore, wild-type p53 seems to be necessary for sensitization to apoptosis, but it is not sufficient because (i) in UMR106 cells with wild-type p53 and normal activation of STAT3, OSM does not activate STAT5 or cell death with Sts and (ii) in non-transformed slowly proliferating mature osteoblasts, OSM activates all the transduction pathways presented here but not cell death. Thus, our screening on cell lines and primary cultures (Table 1 and Supplementary Figure 2) indicates that OSM can sensitize to apoptosis normal or transformed proliferating osteoblasts as well as normal embryonic fibroblasts and breast cancer cells. To respond, OSM should be able to activate p53, STAT5, to increase the Bax/Bcl-2 ratio and thus to sensitize the mitochondria to release cyt c and to activate caspases-9 and -3.
Currently, we do not know whether STAT1, STAT3, STAT5 and/or p53 are also implicated in the induced expression of Bcl-xl, Mcl-1, Bnip-3, Bad, Apaf-1 and p21 WAF1 in OSRGA cells. Because in p53-deficient MG63 osteosarcoma cells, induction of differentiation, growth arrest and protection against apoptosis by OSM depends on STAT3 and p21 WAF1 Jilka et al., 1998) , these results suggest that different STATs are involved in differentiation/cell-cycle arrest/ survival (STAT3) versus sensitization to apoptosis (STAT5). Whereas the action of STAT3 does not require p53, the action of STAT5 does, implying that growth arrest by OSM is not restricted by the p53 status whereas sensitization to apoptosis is only observed in wild-type p53 osteosarcoma (Table 1) .
In osteoblastic cells, OSM induces differentiation into glial/osteocytic cells characterized by reduced osteoblastic markers expression and functions (Chipoy et al., 2004) . Thus, OSM could affect bone formation not only by inducing differentiation but also by sensitizing proliferating osteoblasts to cell death. Whether p53 and STAT5 are implicated in this OSM-induced differentiation of osteoblasts deserves further investigations but recent in vivo studies with p53 knockout mice indicated that p53 inhibits osteoblast differentiation, bone development and neoplasia (Lengner et al., 2006; Wang et al., 2006) . Similarly, STAT5ab À/À mice, although smaller than their wild-type littermates, have an increased number of trabecular osteoblasts and bone formation (Sims et al., 2000) .
In conclusion, we identified p53 and STAT5 as key transcription factors used by OSM to increase Bax and decrease Bcl-2 expression respectively, and thus controlling the mitochondrial cell death pathway in osteosarcoma and proliferating osteoblastic cells. In parallel, strong anti-apoptotic signals are also activated by OSM, via the PKCd and PI3K/Akt pathways. All these events are concomitant with, and most presumably linked to, the OSM-induced differentiation into glial/osteocytic cells, that is, the terminal differentiation of osteoblastic cells. In human osteosarcoma, p53 mutations are frequent and we effectively found that the p53 and/or STAT5 pathways are often disrupted. The use of kinase inhibitors such as Sts in association with OSM could therefore represent new treatments for wild-type p53 osteosarcoma.
Materials and methods
Cell culture and reagents
The rat osteosarcoma OSRGA cell line was described previously (Chipoy et al., 2004) . The rat OSRGA, ROS17/ 2.8 (herein termed ROS) and UMR106, the murine POS-1 (POS), the human MG63, SaOS2, U2OS, MNNG-HOS, MCF-7 and HeLa cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, BioWhittaker, Belgium), supplemented with 5% fetal bovine serum (FBS). The HCT116 cell lines with wild-type or targeted disruption of p53, a kind gift from Drs B Vogelstein and KW Kinzler (Howard Hughes Medical Institute, Baltimore, MD, USA), were cultured in McCoy's 5A medium supplemented with 10% FBS. Mouse BMSC were isolated as described previously (Chipoy et al., 2004) and cultured in DMEM supplemented with 10% FBS. Primary mouse and human osteoblasts, isolated from bone explants as described (Chipoy et al., 2004) , as well as the mouse non-tumoral ST2 and MC3T3-E1 cell lines were cultured in RPMI 1640 (BioWhittaker, Belgium) supplemented with 10% FBS and antibiotics (100 IU/ml penicillin, 100 mg/ml streptomycin). MEF were kindly provided by Dr P Jourdon (Inserm U533, Nantes, France). Cells were treated with mouse (100 ng/ml) or human (50 ng/ml) recombinant OSM (R&D Systems, Minneapolis, MN, USA) and with Sts (Sigma, Saint-Quentin Fallavier, France). Z-VAD-FMK, a pan-caspase inhibitor and the kinase inhibitors LY294002 (PI3K/Akt inhibitor), AktI (Akt inhibitor), UO126 (MEK/ ERK inhibitor) and Rottlerin (PKCd inhibitor) were from Calbiochem (La Jolla, CA, USA). Pifithrin a, a p53 inhibitor, was from Biomol International (Plymouth Meeting, PA, USA).
Cell growth and viability
Cell viability was assessed by Trypan blue exclusion. Dead cells were quantitated after combining non-adherent with adherent cells released from the culture dish using trypsinethylenediaminetetraacetic acid. The percentage of cells exhibiting both nuclear and cytoplasmic Trypan blue staining was determined using a Malassez cell. A minimum of 100 cells were counted.
Cell viability was also determined by XTT assay (Roche, Mannheim, Germany). Cells were plated into 96-wells plates at an initial density of 1500 cells/well, and cultured for 72 h in complete medium with indicated treatments before adding XTT reagents (sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate). After incubation for 5 h at 371C, the absorbance was read at 490 nm. All assays were performed in triplicate.
For cell growth, incorporation of [ 3 H]thymidine (Amersham, Buckinghamshire, UK) was estimated in replicate, subconfluent cell cultures as described previously (Chipoy et al., 2004) .
Time-lapse microscopy OSRGA cells were cultured in 6-well plates for 72 h with or without OSM. Time-lapse experiments begun just after adding Sts for a duration of 14 h. Phase-contrast photos were taken every 10 min through a Leica microscope (Leica, Wetzlar, Germany), then Quick Time movies were edited with the Metamorph software. Cell division and cell death can be observed and apoptotic cells were counted in a time-dependent manner. Each condition was realized in duplicate.
Micro-arrays
Total RNA was isolated using TRIZOL Reagent (Invitrogen, Cergy-Pontoise, France). From the total RNA, 20 mg were reverse-transcribed with incorporation of amino-allyldUTP using the CyScribe Post-Labeling Kit protocol (Amersham RPN5660-X). The amino allyl-modified cDNA were labeled with Cy3 or Cy5. RNA and labeled cDNA quality was assessed using the NanoDrop ND-1000 Spectrophotometer and the Agilent 2100 bioanalyser with RNA LabChip Kits. The Cy3 and Cy5 probes were mixed and hybridized on Human 40 K OciChip or Rat 10 K OciChip. Hybridized arrays were scanned by fluorescence confocal microscopy (Scanarray 3000, GSI-Lumonics). Fluorescence values and expression ratios were analysed using GenePix Pro 5.0 image analysis software (Axon). Consolidated expression values were obtained using MADSCAN (Le Meur et al., 2004) .
Western blot analysis
For total cell lysates, cells were treated as indicated, and then lysed in radioimmunoprecipitation (RIPA) buffer (150 mM NaCl, 5% Tris, pH 7.4, 1% NP-40, 0.25% Na deoxycholate, 1 mM Na 3 VO 4 , 0.5 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin). Lysates were cleared of debris by centrifugation at 12 000 g for 15 min. For mitochondria and cytosol fractions (cyt c release), the cytochrome c release apoptosis assay kit from Calbiochem was used. Protein concentration was determined by the BCA kit (Pierce Chemical, Rockford, IL, USA). Total cell lysate proteins (5-20 mg) were run on 10 or 12% sodium dodecyl sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) and electrophoretically transferred to Immobilon-P membrane (Millipore, Bedford, MA, USA). The membrane was blotted with antibodies to cyt c (Calbiochem), caspase-3, caspase-9, P-p53 (Ser15), Bad, Bax, Bcl-2, Bim, P-Rb (Ser795), P-ERK½ (Thr202/Tyr204), P-PKCd (Thr505), P-Akt (Ser473), Akt, P-STAT1 (Tyr701), P-STAT3 (Tyr705), STAT1 (Cell Signaling Technologies, Beverly, MA, USA), P-Bad (Ser136) (Oncogene, Cambridge, USA), Bak, Mcl-1, p21 WAF1 , STAT3, STAT5 (BD Biosciences, San Diego, CA, USA), Bcl-x, PUMA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or P-STAT5 (Tyr694) (Invitrogen) in PBS, 0.05% Tween 20, and 3% bovine serum albumin (BSA). The membrane was washed and probed with the secondary antibody coupled to horseradish peroxidase. Antibody binding was visualized with the enhanced chemiluminescence system (ECL Kit; Roche). For quantification, the emitted glow was acquired with a CCD camera (Syngene, Cambridge, UK) and analysed with the GeneTools program (Syngene).
For total p53 in OSRGA cells, 700 mg of protein were incubated with an anti-p53 antibody (Santa Cruz Biotechnology) at 41C for 2 h. Immune complexes were isolated using protein G sepharose beads (Sigma), and washed three times with RIPA buffer. The beads were then boiled in SDS sample buffer and analysed by western blotting with antibodies to p53 (Cell Signaling Technologies).
Transfection
Cells were transfected with polyethylenimine (PEI; kind gift from Dr Bruno Pitard; INSERM U533, Nantes, France) using 0.6 ml PEI (10 mM), 100 ml NaCl (150 mM), and 4 mg of DNA for 2 ml of culture medium. The DNA used are pEX-STAT1D38C (lacking 38 C-terminal residues), pDC-STAT3D55C, pDC-STAT5bD40C and pDC-STAT5b full length. The four vectors encoding STATs are a kind gift from Dr H Baumann (Buffalo, NY, USA). Preliminary experiments indicated that transfection of OSRGA cells with the pEGFP(N3) vector (Upstate Biotechnology, Charlottesville, VA, USA) gave around 80% of green fluorescent protein positive (GFP þ ) cells, an efficiency that is high enough to expect modifications in the majority of the cells.
RNA interference
Stably modified OSRGA cells were obtained by lentiviral cell transduction essentially as described previously (Trichet et al., 2006) . Oligonucleotides were designed and cloned into pSUPER to produce the short hairpin RNA shSTAT5 directed against both rat STAT5a and STAT5b genes. The targeted sequence was GATCAAGCTGGGGCACTAT. The cloned oligonucleotides were controlled by sequencing (Genome Express, Meylan, France) before subcloning them with the upstream H1 promoter into the vector pFG12 (Qin et al., 2003) . As a control, a vector pFG12 was developed to produce shRNA targeting LacZ gene as done by Qin et al. (2003) . The resulting constructs allowed the expression of both GFP and target-specific shRNA. They were used for lentivirus production following the protocols provided with the ViraPower Lentiviral Expression System (Invitrogen). A multiplicity of infection of 10 was used to transduce OSRGA cells. Seven days after transduction, GFP þ OSRGA cells were sorted out using FACS.
Caspase-3 activity Caspase-3 activity was assessed on 10 ml of total cell lysates using the kit CaspACE Assay System, Fluorometric (Promega, Madison, WI, USA) following the manufacturer's recommendations. Results were expressed in arbitrary units and corrected for protein content.
Cytochemistry
For STAT5 and p53 localization, OSRGA cells were treated with OSM for indicated times, fixed in 4% methanol, permeabilized in 0.2% Triton X-100 and incubated with primary anti-p53 antibody (diluted 1:200; Santa Cruz Biotechnology) or anti-STAT5 antibody (diluted 1:100; Santa Cruz Biotechnology) in PBS, 1% BSA, 0.1% Triton for 1 h, washed and incubated with secondary antibody (Alexa Fluor 568 goat anti-mouse IgG 2 mg/ml, 1:400 and Alexa fluor 488 goat antirabbit IgG, 2 mg/ml, 1:300, Molecular Probes, Carlsbad, CA, USA) for 45 min. Cover glass fitting was realized with Long Pro Kit (Molecular Probes). Images were collected on a Leica TCS-SP1 confocal microscope (Heidelberg, Germany) with 63/ Â 1.4 oil immertion lens. The digital images were visualized with a 24-bit imaging system including Leica's TCS-NT software and projections were generated from z-stacks.
